Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Cefaclor 375mg modified-release tablets
0501021A0AAAGAG
|
Cefaclor | Cefaclor | Infections | 585 |
|
Cefaclor 500mg capsules
0501021A0AAAEAE
|
Cefaclor | Cefaclor | Infections | 287 |
|
Cefaclor 250mg/5ml oral suspension
0501021A0AAACAC
|
Cefaclor | Cefaclor | Infections | 187 |
|
Cefaclor 125mg/5ml oral suspension
0501021A0AAABAB
|
Cefaclor | Cefaclor | Infections | 100 |
|
Distaclor MR 375mg tablets
0501021A0BBAEAG
|
Distaclor | Cefaclor | Infections | 35 |
|
Distaclor 500mg capsules
0501021A0BBADAE
|
Distaclor | Cefaclor | Infections | 24 |
|
Distaclor 250mg/5ml oral suspension
0501021A0BBACAC
|
Distaclor | Cefaclor | Infections | 13 |
|
Distaclor 125mg/5ml oral suspension
0501021A0BBABAB
|
Distaclor | Cefaclor | Infections | 12 |
|
Cefaclor 125mg/5ml oral suspension sugar free
0501021A0AAAJAJ
|
Cefaclor | Cefaclor | Infections | 2 |
|
Cefaclor 250mg capsules
0501021A0AAAAAA
|
Cefaclor | Cefaclor | Infections | 1 |
|
Bacticlor MR 375mg tablets
0501021A0BEAAAG
|
Bacticlor | Cefaclor | Infections | No data available |
|
Cefaclor 250mg/5ml oral suspension sugar free
0501021A0AAAKAK
|
Cefaclor | Cefaclor | Infections | No data available |
|
Keftid 125mg/5ml oral suspension
0501021A0BDACAJ
|
Keftid | Cefaclor | Infections | No data available |
|
Keftid 250mg capsules
0501021A0BDAAAA
|
Keftid | Cefaclor | Infections | No data available |
|
Keftid 250mg/5ml oral suspension
0501021A0BDADAK
|
Keftid | Cefaclor | Infections | No data available |
|
Keftid 500mg capsules
0501021A0BDABAE
|
Keftid | Cefaclor | Infections | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.